UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
27
UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against The Boeing Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, Jan. 02, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against The Boeing Company (“Boeing” or “the Company”) (NYSE: BA ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's shares between February 8, 2017 and November 13, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before January 28, 2019.

If you are a shareholder who suffered a loss, click here to participate .

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at  www.schallfirm.com , or by email at  brian@schallfirm.com .

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Boeing withheld from the market information about the potential hazards caused by its new flight-control system, which may have contributed to a recent deadly crash in Indonesia. The new automated stall-prevention system allegedly can cause pilots to lose control of the aircraft in certain situations. The pilots of the flight in the Indonesia crash were reportedly not aware that the plane was equipped with the new system, and allegedly not prepared to handle the risk of this occurring. Boeing now faces scrutiny from multiple government and industry officials, including the FAA. Based on these facts, the Company’s public statements throughout the class period were false and materially misleading. When the market learned the truth about Boeing, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm Brian Schall, Esq., Sherin Mahdavian, Esq., www.schallfirm.com 310-301-3335 info@schallfirm.com

SOURCE:

  The Schall Law Firm

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 24

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading

Top 5 Most Recently Viewed Articles

Man Group PLC Highlights Its Strategic Disclosures on Tritax REIT

Updated Category News Views 148

Strategic Position Disclosure by Man Group PLC Man Group PLC is actively sharing its significant interests in the securities market, particularly focusing on its involvement with Tritax Big Box REIT plc. As a key player in the investment landscape, this disclosure marks an important step for the company regarding its strategic holdings. Key Information Pertaining to the...

Continue Reading
TalentLMS and Epignosis Lead the Way in GDPR Compliance

Updated Category News Views 720

TalentLMS and Epignosis Set the Standard for GDPR Compliance TalentLMS, along with its parent company Epignosis, has continuously led the way in providing a fully compliant Learning Management System (LMS) with regards to the General Data Protection Regulation (GDPR). Recent developments affirm that TalentLMS remains the only LMS globally to uphold its commitment to this...

Continue Reading
Zillow and Esusu Forge New Path to Boost Renters' Credit Scores

Updated Category News Views 283

Building Credit for Renters with Zillow and Esusu The recent collaboration between Zillow and Esusu marks a significant step towards empowering renters across the country to build their credit. This partnership allows any renter to report their on-time rent payments, significantly enhancing their credit profiles, for just $20 a year. How the Partnership Works Starting...

Continue Reading
iCrowdNewswire Leverages DeepL for Enhanced Global Communication

Updated Category News Views 121

iCrowdNewswire Enhances Multilingual Capabilities iCrowdNewswire, a prominent international press release distribution company, has embarked on a transformative journey to improve its multilingual services through the introduction of the DeepL API. The integration of DeepL's cutting-edge language AI technology has significantly boosted iCrowdNewswire’s ability to...

Continue Reading
Celebrating Excellence: Top Surgeons Recognized in Endocrine Care

Updated Category News Views 82

Exceptional Recognition for Leading Surgeons in Endocrine Surgery Dr. Jim Norman and Dr. Gary Clayman Acknowledged as Premier Specialists The Hospital for Endocrine Surgery is proud to announce that two of its distinguished surgeons, Dr. Jim Norman and Dr. Gary Clayman, have been honored in the prestigious Castle Connolly Top Doctors list for 2025. This remarkable...

Continue Reading